The brief

Analyst view

• Series D funding of $191M in September 2024 led by Lux Capital brings total to $456M.
• FDA cleared RESTORE Phase 1/2/3 trial of EGEN-2784 in patients with end-stage kidney disease.
• Tim Andrews lived nine months with EGEN-2784 before receiving a human kidney in January 2026.

Technical approach

As reported

Three classes of edits

Triple-layer genetic modification

Knockout of three glycan-antigen genes, insertion of seven human immune-regulation genes, and inactivation of endogenous porcine retroviruses.

69 total modifications

Multiplex precision gene editing

69 edits prevent acute, chronic, and hyperacute rejection while eliminating viral contamination risk.

Pig biology advantage

Organ size and physiology match humans

Pigs reach human-comparable organ size at reasonable maturity timelines, and their organ physiology is more similar to humans than rodents or primates.